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Protective effect of intranasal vaccination of horses
with a modiﬁed live equine herpesvirus type 1 vaccine
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Epizootic Research Center, Equine Research Institute, Japan
Racing Association, Shimotsuke, Tochigi, Japan
Mucosal immunity in the nasal cavity is considered to play an
essential role in protecting horses from disease caused by equine
herpesvirus type 1 (EHV-1), and immunoglobulin A (IgA) anti-
body in the nasal secretions is a key component of this mucosal
immunity. Although intranasal administration of live or killed
EHV-1 vaccines has been attempted with the aim of protecting
horses from viral challenge, induction of virus-speciﬁc IgA after
these vaccinations was not observed, and only slight mitigation of
clinical signs was observed after viral challenge. Here, we
measured immunological responses and performed a challenge
experiment in horses intranasally immunized with a modiﬁed
live EHV-1 vaccine (Nisseiken, Tokyo, Japan) that was originally
licensed for intramuscular injection. Horses (n ¼ 3) were intra-
nasally inoculated with the vaccine (1.3 106 plaque-forming units
[pfu]/10 mL/head) twice with a 4-week interval. Control horses (n
¼ 2) were inoculated in the samewaywith dilutionmedium. Four
weeks after the second dose had been given, the horses were
challenged by intranasal inoculation of EHV-1 (strain 10-I-224,
4.0 106 pfu/10 mL/head). Sequential nasal wash samples were
concentrated by ultraﬁltration and subjected to ELISA to measure
EHV-1-speciﬁc IgA. Viral nasal shedding and viremia were
monitored by virus isolation and real-time PCR. The results of
real-time PCR were considered negative if there were 10 gene
copies in the analyzed sample. EHV-1-speciﬁc IgA levels in the
nasal wash increased in all of the vaccinated horses after two
intranasal doses of vaccine, whereas those in the control horses
remained stable. Serum virus-neutralizing titers also increased in
the vaccinated horses. After viral challenge, pyrexia over 39.0 C
was observed at 1 day post-inoculation (dpi) in both of the control
horses. In contrast, none of the vaccinated horses was pyretic
(over 39.0 C) throughout the experiment, although one horse
had a temperature of 38.7 C at 7 dpi. Viral nasal shedding in the
control horses was detected at 1 to 6 dpi, with a highest mean
gene copy number of 103.8. In contrast, viral nasal shedding in the
vaccinated horses was detected only at 1 to 2 dpi, with a highest
mean gene copy number of 102.3. Viremia was detected in all
horses at 5 to 11 dpi, with individual durations of 2 to 6 days.
Intranasal immunization of horses with the live EHV-1 vaccine
resulted in the production of EHV-1-speciﬁc IgA in the nasal
mucosa and virus-neutralizing antibody in the whole body. Virus
replication in the nasal mucosa after viral challenge was lower in
vaccinated horses than in control horses; virus-speciﬁc IgA0737-0806/$ e see front matter.induced by the intranasal vaccination might have been respon-
sible for this. The absence of pyrexia over 39.0 C in the vaccinated
horses indicated that the immunity induced by intranasal vacci-
nation was effective in protecting horses from EHV-1-induced
pyrexia.
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Equine herpesviruses 1 and 4 (EHV-1 and EHV-4) are members of
the Alphaherpesvirinae subfamily and belong to the genus Vari-
cellovirus. Both viruses are endemic in horse populations
throughout the world and cause severe economic losses. Both vi-
ruses cause respiratory disease; however, only EHV-1 can efﬁ-
ciently transfer fromperipheral bloodmononuclear cells (PBMC) to
endothelial cells lining the blood vessels of the pregnant uterus or
central nervous system, the prerequisite for abortion, perinatal
mortality and neurological disorders (myeloencephalopathy).
EHV-4 can also infect both PBMC and endothelial cells in culture
but does not cause any of the severe complications. We were
interested in studying the differences between EHV-1 and EHV-4
infection of PBMC and how it affects PBMC-endothelial interaction
and disease outcome. Our results indicate that EHV-1 infects B-
lymphocyte and monocyte subpopulations more efﬁciently than
EHV-4. In order to evaluate viral transfer between infected PBMC
and endothelial cells, co-cultivation assays were performed in the
presence of virus neutralizing antibodies. Only EHV-1 was able to
transfer to endothelial cells and viral glycoprotein B (gB) was
shown to be important for this form of cell-to-cell transfer. For
addressing the more dynamic aspects of the interaction, infected
PBMC were allowed to ﬂow (0.5 mm/sec) over endothelial cell
monolayers in the presence of virus neutralizing antibodies. By
simulating the capillary blood ﬂow and analyzing the behavior of
infected PBMC through live ﬂuorescence imaging and automated
cell tracking, we observed that EHV-1 was able to maintain teth-
ering and rolling of infected PBMC more effectively than EHV-4.
Deletion of US3 reduced the ability of infected PBMC to tether and
roll compared to parental virus, which resulted in a signiﬁcant
reduction in virus transfer. We further investigated the expression
and regulation of various adhesion molecules on the surface of
EHV-1 and EHV-4-infected PBMCs. We found that EHV-4, in
contrast to EHV-1, was able to downregulate VLA-4 and LFA-1
adhesion molecules on the surface of infected PBMC. These
